Tsang Raymond S W, Ulanova Marina
Vaccine Preventable Bacterial Diseases, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Northern Ontario School of Medicine, Lakehead University, Thunder Bay, Ontario, Canada.
Vaccine. 2017 Jul 24;35(33):4270-4275. doi: 10.1016/j.vaccine.2017.06.001. Epub 2017 Jun 27.
More than two decades after the implementation of the Hib conjugate vaccine in North America, Haemophilus influenzae serotype a (Hia) has emerged as a significant cause of invasive disease in Indigenous communities. However, little is known about the global presence of this pathogen.
We interrogated the H. influenzae Multi-Locus Sequence Typing (MLST) website (https://pubmlst.org/hinfluenzae/) by selecting for serotype a records. We also updated our previous literature review on this subject matter.
Hia has been reported from at least 35 countries on six major continents. However, most Hia diseases were associated with Indigenous communities. Clonal analysis identified two clonal populations with one typified as ST-23 responsible for most invasive disease in North America and being the predominant clone described on the H. influenzae MLST website. Incidence of invasive Hia disease in Indigenous communities in North America are similar to the rates of Hib disease reported prior to the Hib conjugate vaccine era. Hia causes severe clinical diseases, such as meningitis, septicaemia, pneumonia, and septic arthritis with case-fatality rates between 5.6% and 33% depending on the age of the patient and the genetic makeup of the Hia strain.
Although invasive Hia disease can be found globally, the current epidemiological data suggest that this infection predominantly affects Indigenous communities in North America. The clinical disease of Hia and the clonal nature of the bacteria resemble that of Hib. The high incidence of invasive Hia disease in Indigenous communities, along with potential fatality and severe sequelae causing long-term disability in survivors, may support the development of a new Hia conjugate vaccine for protection against this infection similar in design to the one introduced in the 1990s to control invasive Hib disease.
在北美实施b型流感嗜血杆菌结合疫苗二十多年后,a型流感嗜血杆菌(Hia)已成为原住民社区侵袭性疾病的一个重要病因。然而,对于这种病原体在全球的存在情况知之甚少。
我们通过选择a型血清型记录来查询流感嗜血杆菌多位点序列分型(MLST)网站(https://pubmlst.org/hinfluenzae/)。我们还更新了之前关于该主题的文献综述。
六大洲至少35个国家报告了Hia。然而,大多数Hia疾病与原住民社区有关。克隆分析确定了两个克隆群体,其中一个以ST-23为代表,它是北美大多数侵袭性疾病的病因,也是流感嗜血杆菌MLST网站上描述的主要克隆。北美原住民社区侵袭性Hia疾病的发病率与b型流感嗜血杆菌结合疫苗时代之前报告的Hib疾病发病率相似。Hia会引发严重的临床疾病,如脑膜炎、败血症、肺炎和化脓性关节炎,病死率在5.6%至33%之间,具体取决于患者年龄和Hia菌株的基因构成。
虽然侵袭性Hia疾病在全球都有发现,但目前的流行病学数据表明,这种感染主要影响北美原住民社区。Hia的临床疾病和细菌的克隆性质与Hib相似。原住民社区侵袭性Hia疾病的高发病率,以及幸存者中可能出现的致命性和导致长期残疾的严重后遗症,可能支持研发一种新的Hia结合疫苗来预防这种感染,其设计类似于20世纪90年代推出的用于控制侵袭性Hib疾病的疫苗。